Glasswing Ventures Leads $4M Seed Investment in Agentic Pharmaceutical Platform Asepha

It is with great enthusiasm that we announce our Seed investment in Asepha, the AI-native clinical automation platform leveraging AI agents to streamline prescription processing, medication reconciliation, and documentation for pharmacies globally. With 7.8 billion prescriptions processed annually across the United States, Canada, and Australia, Asepha’s automation of core pharmacy workflows addresses a $6.8 billion annual market opportunity.

As annual prescription volumes have continuously increased, growing by 12% over the past decade in the United States alone, the number of people pursuing careers in pharmaceuticals has continuously decreased. This deficit challenges pharmacists to accurately fulfill prescription requests on time. By automating much of a pharmacist’s administrative workflow, Asepha enables staff to prioritize patient care without requiring additional headcount or working excessive hours.

Asepha’s agentic platform seamlessly integrates into existing systems and tools, so pharmacists can continue with their normal processes while its agents perform real-time, web-based tasks in parallel, reducing prescription processing time by upwards of 90%. The platform’s human-in-the-loop feature incorporates feedback from domain experts to ensure that Asepha’s AI continuously improves and that patient safety is never compromised during the learning process.

Asepha’s founding team comprises a blend of industry and technical talent that positions the company to excel at transforming the pharmaceutical industry. As a licensed pharmacist with both inpatient and outpatient experience, Eunice Wu, CEO and Co-founder of Asepha, intimately understands pharmacists’ pain points. Wu earned her Doctor of Pharmacy from the University of British Columbia, where she completed an internship as an inpatient pharmacist at BC Children’s Hospital and Sunny Hill Health Centre for Children. She previously worked as an outpatient pharmacist at Shoppers Drug Mart, one of Canada’s largest pharmacy chains.

Co-founder and CTO Can Uncu is a technical builder with a passion for quantitative testing and systemic iteration. Uncu previously worked at AMD, where he developed products such as the MI300X chip, which powers OpenAI and Microsoft Azure. Wu and Uncu met while participating in the CanadaNEXT accelerator program, where they found a mutual interest in leveraging advanced technologies to assist professionals in heavily regulated industries.

We are excited to welcome Asepha to the Glasswing family and look forward to partnering with the team as it drives efficiency and reduces costs for pharmacies around the world.

To learn more about Asepha and the funding round, see here.